Brief: Quantum Genomics Enters Into Exclusive Agreement With Dongwha Pharm
02/12/2020 16:45
Dec 2 (Reuters) - Quantum Genomics SA ALQGC.PA :
* QUANTUM GENOMICS ENTERS INTO EXCLUSIVE LICENSING AND
COLLABORATION AGREEMENT WITH DONGWHA PHARM
* QUANTUM GENOMICS TO RECEIVE UP TO $18.5 MILLION IN UPFRONT
AND
MILESTONE PAYMENTS PLUS DOUBLE-DIGIT ROYALTIES ON SALES
* DONGWHA PHARM TO RECEIVE AN EXCLUSIVE LICENSE TO DEVELOP
AND
COMMERCIALIZE FIRIBASTAT FOR TREATMENT OF DIFFICULT TO
TREAT/RESISTANT HYPERTENSION IN SOUTH KOREA
Source text for Eikon: ID:nACT66336
Further company coverage: ALQGC.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))
Recent news on Quantum Genomics SA
See all newsBrief: Quantum Genomics Announces Resumption Of Discussions With HealthTech, Terminates Exclusive Negotiations With Vistacare Medical
Brief: Quantum Genomics Enters Into Exclusive Negotiations With Vistacare Medical
Brief: Quantum Genomics To Reduce Staff; Jean-Philippe Milon Becomes President and CEO
Brief: Quantum Genomics In Talks For New Strategic Project
Brief: Quantum Genomics Announces Lack Of Significant Efficacy For Firibastat In Their Phase Iii Study